Answers are grounded in this paper and cite their sources.
Cancer is a major global concern due to its high mortality rate. Tumor immunotherapy has revolutionized cancer treatment. However, low response rates and immune-related complications remain challenges. Extracellular vesicles (EVs), including exosomes, have emerged as promising therapeutic tools for various pathological conditions, especially cancer. Evidence indicates that changes in the quantity and composition of EVs can influence the immunosuppressive tumor microenvironment, potentially affecting the effectiveness of immunotherapy. Exploiting EVs for immune sensitization has generated significant clinical interest. This review provides an in-depth understanding of the origin of EVs, their therapeutic applications (such as drug delivery nanoplatforms and cancer immunotherapies, including vaccines), diagnostic potential as tumor biomarkers, ongoing EV-based clinical trials, and the challenges encountered in EV-based cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Manoochehri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: